Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ibotta, Inc. stock logo
IBTA
Ibotta
$37.03
+0.3%
$44.01
$31.40
$79.80
$934.46M-1.29320,103 shs265,537 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$2.15
+1.4%
$2.22
$2.00
$5.20
$225.60M1.23613,849 shs436,971 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$6.72
-2.7%
$7.43
$6.08
$19.12
$889.28M1.631.31 million shs1.41 million shs
Willdan Group, Inc. stock logo
WLDN
Willdan Group
$79.67
+1.4%
$59.41
$30.43
$80.75
$1.14B1.25164,655 shs359,955 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ibotta, Inc. stock logo
IBTA
Ibotta
+0.19%-0.75%-5.25%-22.27%-47.48%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+1.42%-5.70%0.00%-17.62%-57.17%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-2.75%-10.28%-3.86%-29.63%-56.65%
Willdan Group, Inc. stock logo
WLDN
Willdan Group
+1.43%+9.63%+38.46%+107.04%+138.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ibotta, Inc. stock logo
IBTA
Ibotta
2.9203 of 5 stars
4.41.00.00.01.11.71.3
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.9438 of 5 stars
3.54.00.00.02.21.70.6
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
4.0311 of 5 stars
4.23.00.00.02.83.31.3
Willdan Group, Inc. stock logo
WLDN
Willdan Group
4.1804 of 5 stars
1.55.00.04.14.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ibotta, Inc. stock logo
IBTA
Ibotta
2.83
Moderate Buy$61.6066.35% Upside
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.00
Buy$7.50248.84% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.45
Hold$13.83105.85% Upside
Willdan Group, Inc. stock logo
WLDN
Willdan Group
3.00
Buy$51.50-35.36% Downside

Current Analyst Ratings Breakdown

Latest MXCT, IBTA, NEO, and WLDN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Willdan Group, Inc. stock logo
WLDN
Willdan Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/16/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $65.00
5/15/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/15/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$42.00 ➝ $55.00
5/15/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$58.00 ➝ $58.00
5/15/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$52.00 ➝ $60.00
5/15/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $70.00
5/15/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
5/6/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00
5/1/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $10.00
4/30/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ibotta, Inc. stock logo
IBTA
Ibotta
$367.25M2.55$2.52 per share14.67$14.77 per share2.51
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$38.63M5.92N/AN/A$1.95 per share1.10
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$660.57M1.31$0.43 per share15.75$7.03 per share0.96
Willdan Group, Inc. stock logo
WLDN
Willdan Group
$565.80M2.04$3.14 per share25.37$16.59 per share4.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ibotta, Inc. stock logo
IBTA
Ibotta
$68.74M$1.4825.023.0816.24%15.04%9.71%8/13/2025 (Confirmed)
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/5/2025 (Estimated)
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$78.73M-$0.61N/A74.67N/A-11.54%-2.21%-1.22%7/29/2025 (Estimated)
Willdan Group, Inc. stock logo
WLDN
Willdan Group
$22.57M$1.6947.1440.04N/A4.08%13.74%6.98%8/7/2025 (Confirmed)

Latest MXCT, IBTA, NEO, and WLDN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Willdan Group, Inc. stock logo
WLDN
Willdan Group
$0.72N/AN/AN/A$161.00 millionN/A
8/5/2025Q2 2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10N/AN/AN/A$9.57 millionN/A
7/29/2025Q2 2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$0.0279N/AN/AN/A$182.91 millionN/A
5/14/2025Q1 2025
Ibotta, Inc. stock logo
IBTA
Ibotta
$0.01$0.02+$0.01$0.02$81.70 million$84.57 million
5/7/2025Q1 2025
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million
4/29/2025Q1 2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.02-$0.08-$0.06-$0.20$171.38 million$168.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ibotta, Inc. stock logo
IBTA
Ibotta
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
Willdan Group, Inc. stock logo
WLDN
Willdan Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A
2.69
2.69
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
12.23
11.58
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.38
2.05
1.95
Willdan Group, Inc. stock logo
WLDN
Willdan Group
0.35
1.61
1.61

Institutional Ownership

CompanyInstitutional Ownership
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%
Willdan Group, Inc. stock logo
WLDN
Willdan Group
72.29%

Insider Ownership

CompanyInsider Ownership
Ibotta, Inc. stock logo
IBTA
Ibotta
16.08%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.30%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.40%
Willdan Group, Inc. stock logo
WLDN
Willdan Group
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A25.31 million21.24 millionN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
80106.42 million102.90 millionOptionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,200128.70 million125.61 millionOptionable
Willdan Group, Inc. stock logo
WLDN
Willdan Group
1,76114.50 million13.25 millionOptionable

Recent News About These Companies

WLDN - Willdan Group Inc Executives - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ibotta stock logo

Ibotta NYSE:IBTA

$37.03 +0.11 (+0.30%)
As of 07/17/2025 03:58 PM Eastern

Ibotta’s mission is to Make Every Purchase Rewarding. Our technology allows CPG brands to deliver digital promotions to over 200 million consumers through a single, convenient network called the Ibotta Performance Network (IPN). We are pioneers in success-based marketing: we only get paid when our client’s promotion results in a sale, not when a consumer merely views or clicks on the promotion. We have built the largest digital item-level promotions network in the United States by forming strategic relationships with major retailers such as Walmart Inc. (Walmart) and Dollar General Corporation (Dollar General), which use our digital offers to power their loyalty programs on a white-label basis. Through the IPN, our clients can also reach millions more consumers on our widely used rewards app digital properties, which include the Ibotta-branded cash back mobile app, website, and browser extension (collectively, Ibotta D2C). We work directly with over 850 different clients, representing over 2,400 different CPG brands to source exclusive offers as of December 31, 2023. Most of our offers cover products in non-discretionary categories, such as grocery, but we also work with general merchandise manufacturers in categories such as toys, clothing, beauty, electronics, pet, home goods, and sporting goods. Over time, our clients have generally ramped up their spend with us, and they rarely drop off our network. In fact, of our top 100 clients, 96% were retained from 2022 to 2023. Our technology platform uses an Artificial Intelligence (AI)-enabled offer engine that is designed to match and distribute the right offer to the right consumer at the right time. This is possible because we receive a large volume of item-level purchase data through our secure point of sale (POS) integrations with 85 different retailers as of December 31, 2023. Using this data, we form a profile of each consumer based on what they have bought in the past and how they have responded to various price promotions. From there, we build recommenders that are driven by machine learning and designed to create personalized savings experiences for each consumer. The more data we accumulate, the smarter our recommenders become. Whatever our clients’ specific objectives may be – such as encouraging brand switching, shortening purchase cycles, incentivizing consumers to stock up, or promoting around key seasonal events – our platform helps them design a promotional campaign to accomplish their goals. Ibotta’s technology tracks which offers are selected by consumers, matches offers to the products that have been purchased, logs redemptions, handles the flow of funds, and takes care of all downstream billing and logistics. We perform the function of “air traffic control,” meaning our network enables offers to be matched, distributed, and redeemed across multiple large third-party publishers in a coordinated fashion. This minimizes the risks that offer budgets are exceeded and that consumers redeem the same offer several times for a single purchase (i.e., offer stacking). Our client tools allow CPG brands to set up campaigns, monitor redemption and budget levels, and analyze overall campaign performance – all in a single, convenient interface. We deliver success-based digital promotions at-scale because we manage a growing, open network of third-party publishers that host our offers. Retailers are among our most important publishers because their apps and websites are frequently visited by consumers with high purchase intent. A retailer may ingest digital offers from Ibotta’s Application Programming Interface (API) and present them to its consumers as part of its own branded loyalty program. We call these partners “retailer publishers.” We believe retailer publishers choose to work with Ibotta because we are a trusted partner that can provide a large universe of exclusive offers coupled with a set of plug and play capabilities that would be difficult for them to create and scale on their own. For example, Ibotta and Walmart entered into a multi-year strategic relationship that makes Ibotta the exclusive provider of digital item-level rebate offer content for Walmart U.S., across all product categories, for online and offline shopping. Consumers redeem our offers on Walmart properties without ever creating an Ibotta account. Instead, they can select manufacturer offers from the Walmart website or app, buy the featured items in-store or online, and instantly earn Walmart Cash which can be applied to future purchases in a Walmart store or on Walmart.com. All CPG brands wishing to run digital item-level rebates on Walmart’s website can only do so through the IPN. Ibotta also partners with several other leading retailer publishers. For example, Ibotta partners with Family Dollar, a subsidiary of Dollar Tree, Inc. We also work indirectly to publish offers on certain retailer properties, including Kroger (powering Kroger Cash) and Shell (powering Shell Fuel Rewards). In addition to providing digital offers for retailers, Ibotta also makes the same offers available on its own digital properties, which include Ibotta D2C. Since 2012, over 50 million Americans have registered for our free app. Ibotta D2C reaches a highly engaged audience of savings-conscious consumers who want a single digital starting point where they can find cash back offers across a variety of retailers. Many of these consumers decide where to shop based on the availability of deals in different retailers. Once the IPN launched, Ibotta D2C became a publisher on the IPN, meaning it is now one of many nodes through which our digital offers are delivered to the end consumer. In the future, we believe the IPN may be extended to other publishers across a variety of new verticals. For example, new publishers could include delivery services, banks, or other apps and websites that want to give their consumers access to offers on popular everyday items without having to source those offers from thousands of different CPG brands or secure item-level data from multiple integrated retailers where the offers can be redeemed. We believe Ibotta is well positioned to capitalize on a large and growing market opportunity. U.S. consumers spent approximately $1.2 trillion dollars in the grocery sector in 2023. CPG brands compete fiercely to influence consumer spending habits, spending approximately $200 billion on marketing annually in the United States. In fact, no other industry spends more on marketing, as a percentage of overall budgets, than CPG. Most of our revenue is redemption revenue which is generated from redemptions of offers across the IPN. A significant portion of that redemption revenue arises from offer redemptions on third-party publishers. We also generate revenue by selling ad products on our Ibotta D2C properties. Specifically, we allow CPG brands and retailers to enhance awareness of their offers by buying display ads, in-app videos, or email marketing campaigns. We also charge partners a licensing fee to leverage our aggregated data in ways that help them better understand their target consumers and improve their promotional activities. Finally, on Ibotta’s D2C properties, we also allow thousands of online retailers to advertise and present consumers with their own sitewide cash back offers. These clients benefit from the incremental sales generated by Ibotta’s savings-conscious audience. Our revenue growth significantly accelerated with the addition of new publishers to the IPN. Most recently, the rollout of our offers on the digital property of Walmart has attracted larger audiences, and in turn, resulted in greater spend by CPG brands and a greater number of redeemed offers. These developments have increased our scale, growth and profitability. • Total revenue grew from $210.7 million in 2022 to $320.0 million in 2023, an increase of 52%; • Redemption revenue grew from $138.7 million (or 66% of total revenue) in 2022 to $243.9 million (or 76% of total revenue) in 2023, an increase of 76%; • Gross profit grew from $164.5 million in 2022 to $276.0 million in 2023, an increase of 68%; • Net income (loss) improved from $(54.9) million in 2022 to $38.1 million in 2023; • Net income (loss) as a percent of revenue improved from (26)% in 2022 to 12% in 2023; and • Adjusted EBITDA margin improved from (13)% in 2022 to 26% in 2023. We were incorporated in 2011 as Zing Enterprises, Inc., a Delaware corporation. In 2012, we changed our name to Ibotta, Inc. Our principal executive office is located at 1801 California Street, Suite 400, Denver, Colorado.

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$2.15 +0.03 (+1.42%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$2.16 +0.01 (+0.47%)
As of 07/17/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

NeoGenomics stock logo

NeoGenomics NASDAQ:NEO

$6.72 -0.19 (-2.75%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$6.74 +0.02 (+0.30%)
As of 07/17/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Willdan Group stock logo

Willdan Group NASDAQ:WLDN

$79.67 +1.12 (+1.43%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$80.34 +0.67 (+0.84%)
As of 07/17/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Willdan Group, Inc., together with its subsidiaries, provides professional, technical, and consulting services primarily in the United States. It operates in two segments, Energy, and Engineering and Consulting. The Energy segment offers comprehensive audit and surveys, program design and implementation, master planning, demand reduction, grid optimization, benchmarking analyses, design engineering, construction management, performance contracting, installation, alternative financing, measurement and verification services, and software and data analytics, as well as energy consulting and engineering, turnkey facility and infrastructure projects, and customer support services. The Engineering and Consulting segment provides building and safety, city engineering and code enforcement, development plan review and inspection, disaster recovery, geotechnical and earthquake engineering, planning and surveying, contract staff support, program and construction management, structural engineering, transportation and traffic engineering, and water resources services. This segment also offers district administration, financial consulting, and federal compliance services. It serves public and governmental agencies, including cities, counties, redevelopment agencies, water districts, school districts, and universities; investor and municipal owned energy utilities; state and federal agencies; and commercial and industrial firms, as well as various other special districts and agencies. The company was founded in 1964 and is headquartered in Anaheim, California.